Effects of eplerenon in chronik kidney disease with hypertension

Effects of eplerenon in chronik kidney disease with hypertension - Eplerenon in chronik kidney disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010789

Enrollment

Registered

2013-05-23

Start date

2013-05-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronick kidney disease with hypertension

Interventions

eplerenone 50-100mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) >=20 years old 2)chronic kidney disease patients whose eGFR is over 60ml/min/1.73m2 3)hypertension(140/90 mmHg) irrespected of antihypertensive therapy

Exclusion criteria

Exclusion criteria: 1)diabetes mellitus with microalbuminuria or proteinuria 2)patinets who have allegry for eplerenon 3)hyperkalemia (> 5.5 mEq/ml) 4)chronic kidney disease patients whose eGFR is under 50ml/min/1.73m2 5)severe liver dysfunction 6)patinets who are taking potassiums or potassium-sparing diuretics 7)pregnant women 8)patinets who are taking itraconazole, ritonavir or nelfinavir 9)patinets who will not give informed concent

Design outcomes

Primary

Measure	Time frame
The change of blood pressure, heart function, renal function	—

Countries

Japan

Contacts

Public ContactYoshiyuki Morishita

Jichi Medical University Division of Nephrology, Department of Internal medicine

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026